Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet, 2019;393: 768–777.
Implications for practice and research
Largest meta-analysis for Generalised Anxiety Disorder (GAD) to date synthesising 89 trials.
Adds ability to make research-based clinical decisions about medications for GAD that were not only funded from pharmaceutical companies.
Future research, to determine the benefits of these identified medications concurrently with GAD and depression, may be a clinically helpful next step.
There are often discrepancies in healthcare in relation to the best pharmaceutical approaches to corresponding ailments. Mental health and psychopharmacology are no exception given the multitudes of medication and research which although helpful, may make clinical decisions more confusing. This paper identified the volumes of evidence surrounding psychopharmacology for Generalised Anxiety Disorder (GAD) which existed in isolated databases making it difficult to navigate, and drew helpful and practical conclusions. The results …
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.